Subthalamic glutamic acid decarboxylase gene therapy: Changes in motor function and cortical metabolism

Journal of Cerebral Blood Flow and Metabolism

Volumn 27, Issue 3, 2007, Pages 501-509

  Emborg, Marina E ^a,b   Carbon, Maren ^c   Holden, James E ^a,b,d   During, Matthew J ^e   Ma, Yilong ^c   Tang, Chengke ^c   Moirano, Jeffrey ^a,b,d   Fitzsimons, Helen ^e   Roitberg, Ben Z ^f   Tuccar, Eray ^f   Roberts, Andrew ^b,d   Kaplitt, Michael G ^g   Eidelberg, David ^c,h  

^a UNIVERSITY OF WISCONSIN   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

^c FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

^d UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^g WEILL CORNELL MEDICAL COLLEGE   (United States)

^h NONE   (United States)

Author keywords

Gene therapy; Glucose metabolism; Glutamic acid decarboxylase (GAD); Parkinson's disease; Positron emission tomography

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; ADENOVIRUS VECTOR; FLUORODEOXYGLUCOSE F 18; GLUCOSE; GLUTAMATE DECARBOXYLASE;

ADENO ASSOCIATED VIRUS; ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN METABOLISM; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GENE THERAPY; GLUCOSE METABOLISM; GLUCOSE UTILIZATION; HISTOLOGY; MOTOR CORTEX; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; SUBTHALAMIC NUCLEUS;

ANIMALS; DEPENDOVIRUS; FEMALE; GENE THERAPY; GENETIC VECTORS; GLUTAMATE DECARBOXYLASE; MACACA MULATTA; MOTOR ACTIVITY; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; SUBTHALAMIC NUCLEUS; TRANSFECTION;

EID: 33847198228     PISSN: 0271678X     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.jcbfm.9600364     Document Type: Article

References (43)

1. Alvarez L, Macias R, Guridi J (2001) Dorsal subthalamotomy for Parkinson's disease. Mov Disord 16:72-8
2. Bankiewicz KS, Eberling JL, Kohutnicka M, Jagust W, Pivirotto P, Bringas J, Cunningham J, Budinger TF, Harvey-White J (2000) Convection-enhanced delivery of AAV vector in parkinsonian monkeys; in vivo detection of gene expression and restoration of dopaminergic function using pro-drug approach. Exp Neurol 164:2-14
3. Baron M, Wichmann T, Ma D, DeLong MR (2002) Effects of transient focal inactivation of the basal ganglia in parkinsonian primates. J Neurosci 22:592-9
4. Benabid AL, Pollak P, Gao D, Hoffmann D, Limousin P, Gay E, Payen I, Benazzouz A (1996) electrical stimulation of the ventralis intermedius nucleus of the thalamus as a treatment of movement disorders. J Neurosurg 84:203-14
5. Black KJ, Koller JM, Snyder AZ, Perlmutter JS (2001) Template images for nonhuman primate neuroimaging: 2. Macaque. NeuroImage 14:744-8
6. Brown P, Oliviero A, Mazzone P, Insola A, Tonali P, Di Lazzaro V (2001) Dopamine dependency of oscillations between subthalamic nucleus and pallidum in Parkinson's disease. J Neurosci 21:1033-8
7. Brownell A, Canales K, Chen YI, Jenkins BG, Owen C, Livni E, Yu M, Cicchetti F, Sanchez-Pernaute R, Isacson O (2003) Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model. NeuroImage 20:1064-75
8. Cannestra AF, Santori EM, Holmes CJ, Toga AW (1997) A three-dimensional multimodality brain map of the nemestrina monkey. Brain Res Bull 43:141-8
9. Carbon M, Eidelberg D (2002) Modulation of regional brain function by deep brain stimulation: studies with positron emission tomography. Curr Opin Neurol 15:451-5
10. Chatton J, Pellerin L, Magistretti PJ (2003) GABA uptake in astrocytes is not associated with significant metabolic cost: implications for brain imaging of inhibitory transmission. Proc Natl Acad Sci USA 100:12456-61
11. Chen Q, He Y, Yang K (2005) Gene therapy for Parkinson's disease: progress and challenges. Curr Gene Ther 5:71-80
12. Drouot X, Oshino S, Jarraya B, Besret L, Kishima H, Remy P, Dauguet J, Lefaucheur JP, Dolle F, Conde F, Bottlaender M, Peschanski M, Keravel Y, Hantraye P, Palfi S (2004) Functional recovery in a primate model of Parkinson's disease following motor cortex stimulation. Neuron 44:769-78
13. During MJ, Kaplitt MG, Stern MB, Eidelberg D (2001) Subthalamic GAD gene transfer in Parkinson disease patients who are candidates for deep brain stimulation. Hum Gene Ther 12:1589-91
14. Eckert T, Eidelberg D (2005) Neuroimaging and therapeutics in movement disorders. NeuroRx 2:361-71
15. Eidelberg D, Moeller JR, Dhawan V, Spetsieris P, Takikawa S, Ishikawa T, Chaly T, Robeson W, Margouleff D, Przedborski S et al. (1994) The metabolic topography of parkinsonism. J Cereb Blood Flow Metab 14:783-801
16. Eidelberg D, Moeller JR, Ishikawa T, Dhawan V, Spetsieris P, Silbersweig D, Stern E, Woods RP, Fazzini E, Dogali M, Beric A (1996) Regional metabolic correlates of surgical outcome following unilateral pallidotomy for Parkinson's disease. Ann Neurol 39:450-9
17. Emborg M (2004) Evaluation of animal models of Parkinson's disease for neuroprotective strategies. J Neuroci Methods 139:121-43
18. Emborg M, Ma S, Mufson E, Levey A, Taylor M, Brown W, Holden JE, Kordower JH (1998) Age-related declines in nigral neuronal function correlate with motor impairments in rhesus monkeys. J Comp Neurol 401:253-65
19. Emborg M, Moirano J, Schafernak K, Moirano M, Evans M, Konecny T, Roitberg B, Ambarish P, Mangubat E, Ma Y, Eidelberg D, Holden JE, Kordower JH, Leestma JE (2006) Basal ganglia lesions after MPTP administration in rhesus monkeys. Neurobiol Dis, in press [Epub ahead of print]
20. Emborg-Knott ME, Domino EF (1998) MPTP induced asymmetric parkinsonism in nonhuman primates 6 to 8 years after a unilateral intracarotid (ica) dose. Exp Neurol 152:214-20
21. Forno L, Nagy D, Conway J, Emborg M, McLaughlin WW, Bankiewicz KS (1995) Acute effect on the basal ganglia of intracartotid administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to rhesus monkeys. Soc. Neurosci 21:1256
22. Fukuda M, Mentis MJ, Ma Y, Dhawan V, Antonini A, Lang AE, Lozano AM, Hammerstad J, Lyons K, Koller WC, Moeller JR, Eidelberg D (2001) Networks mediating the clinical effects of pallidal brain stimulation for Parkinson's disease: A PET study of resting state glucose metabolism. Brain 124:1601-9
23. Hamani C, Lozano A (2003) Physiology and pathophysiology of Parkinson's disease. Ann NY Acad Sci 991:15-21
24. Herzog R, Hagstrom J, Kung S, Tai S, Wilson J, Fisher K, High K (1997) Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Natl Acad Sci USA 94:5804-9
25. Kordower JH, Bloch J, Ma SY, Chu Y, Palfi S, Roitberg B, Emborg M, Hantraye P, Deglon N, Aebischer P (1999) Lentiviral gene transfer to the nonhuman primate brain. Exp Neurol 160:1-16
26. Kordower JH, Emborg M, Bloch J, Ma S, Chu Y, Leventhal L, McBride J, Chen E, Palfi S, Roitberg B, Brown W, Holden JE, Pyzalski R, Taylor M, Carvey P, Ling Z, Trono D, Hantraye P, Deglon N, Aebischer P (2000) Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 290:767-73
27. Kurlan R, Kim M, Gash D (1991) Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov Disord 6:111-8
28. Lee B, Lee H, Nam YR, Oh JH, Cho YH, Chang JW (2005) Enhanced expression of glutamate decarboxylase 65 improves symptoms of rat parkinsonian models. Gene Therapy 12:1215-22
29. Levy R, Lang AE, Dostrovsky J, Pahapill P, Romas J, Saint-Cyr J, Hutchinson WD, Lozano A (2001) Lidocaine and muscimol microinjections in subthalamic nucleus reverse parkinsonian symptoms. Brain 124:2105-18
30. Lozano A, Mahant N (2004) Deep brain stimulation surgery for Parkinson's disease: mechanisms and consequences. Parkinsonism Relat Disord 10:S49-57
31. Luo J, Kaplitt MG, Fitzsimons HL, Zuzga DS, Liu Y, Oshinsky ML, During MJ (2002) Subthalamic GAD gene therapy in a Parkinson's disease rat model. Science 298:425-9
32. Moeller JR, Nakamura T, Mentis MJ, Dhawan V, Spetsieres P, Antonini A, Missimer J, Leenders KL, Eidelberg D (1999) Reproducibility of regional metabolic covariance patterns: comparison of four populations. J Nucl Med 40:1264-9
33. Oh MY, Abosch A, Kim SH, Lang AE, Lozano AM (2002) hardware-related complications of deep brain stimulation. Neurosurgery 50:1268-74
34. Palombo E, Porrino LJ, Bankiewicz KS, Crane AM, Sokoloff L, Kopin IJ (1990) Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. J Neurosci 10:860-9
35. Rodriguez-Oroz MC, Obeso J, Lang AE, Houeto JL, Pollak P, Rehncrona S, Kulisevsky J, Albanese A, Volkmann J, Hariz MI, Quinn NP, Speelman JD, Guridi J, Zamarbide I, Gironell A, Molet J, Pascual-Sedano B, Pidoux B, Bonnet AM, Agid Y, Xie J, Benabid AL, Lozano A, Saint-Cyr J, Romito L, Contarino MF, Scerrati M, Fraix V, Van Blercom N (2005) Bilateral deep brain stimulation in Parkinson's disease: a multicentre study with 4 years follow-up. Brain 128:2240-9
36. Sestini S, Ramat S, Formiconi AR, Ammannati F, Sorbi S, Pupi A (2005) Brain networks underlying the clinical effects of long-termsubthalamic stimulation for Parkinson's disease: a 4-year follow-up study with rCBF SPECT. J Nucl Med 46:1444-54
37. Stefurak T, Mikulis D, Mayberg H, Lang AE, Hevenor S, Pahapill P, Saint-Cyr J, Lozano A (2003) Deep brain stimulation for Parkinson's disease dissociates mood and motor circuits: a functional MRI casestudy. Mov Disord 18:1508-41
38. Stephenson DT, Li Q, Simmons C, Connell MA, Meglasson MD, Merchant K, Emborg M (2005) Expression of GAD65 and GAD67 immunoreactivity in MPTP-treated monkeys with or without L-DOPA administration. Neurobiol Dis 20:347-59
39. Su P, Tseng HM, Liu HM, Yen RF, Liou HH (2003) Treatment of advanced Parkinson's disease by subthalamotomy: one year results. Mov Disord 18:531-8
40. Thomas C, Storm T, Huang Z, Kay M (2004) Rapid uncoating of vector genomes is the key to efficient liver transduction with pseudotyped adeno-associated virus vectors. J Virol 78:3110-22
41. Trošt M, Su S, Su PC, Yen R-F, Tseng H-M, Barnes A, Ma Y, Eidelberg D (2006) Network modulation by the subthalamic nucleus in the treatment of Parkinson's disease. NeuroImage 31:301-7
42. Wenzelburger R, Kopper F, Zhang B, Witt K, Hamel W, Weinert D, Kuhtz-Buschbeck J, Golge M, Illert M, Deuschl G, Krack P (2003) Subthalamic nucleus stimulation for Parkinson's disease preferentially improves akinesia of proximal arm movements compared tofinger movements. Mov Disord 18:1162-9
43. Wichmann T, DeLong MR (1998) Models of basal ganglia function and pathophysiology of movement disorders. Neurosurg Clin N Am 9:223-36